121 related articles for article (PubMed ID: 2117485)
21. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
22. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
23. Current safety of clotting factor concentrates.
Epstein JS; Fricke WA
Arch Pathol Lab Med; 1990 Mar; 114(3):335-40. PubMed ID: 2407224
[TBL] [Abstract][Full Text] [Related]
24. [Transfusion-associated HIV infection].
Gürtler LG; Eberle J; Bader L
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():7-10. PubMed ID: 8000258
[TBL] [Abstract][Full Text] [Related]
25. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1985; 35(11):1617-9. PubMed ID: 3004516
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of HTLV-III/LAV, hepatitis B and non-A/non-B viruses by pasteurization in human plasma protein preparations.
Mauler R; Merkle W; Hilfenhaus J
Dev Biol Stand; 1987; 67():337-51. PubMed ID: 3111911
[TBL] [Abstract][Full Text] [Related]
27. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
28. [Transmission of HIV infection].
Tomaso H; Reisinger EC; Grasmug E; Ramschak H; Krejs GJ
Wien Klin Wochenschr; 1995; 107(3):85-90. PubMed ID: 7886967
[TBL] [Abstract][Full Text] [Related]
29. Horizontal versus vertical transmission of human immunodeficiency virus type 1 (HIV-1). Experience from southwestern Saudi Arabia.
al-Nozha MM; al-Frayh AR; al-Nasser M; Ramia S
Trop Geogr Med; 1995; 47(6):293-5. PubMed ID: 8650743
[TBL] [Abstract][Full Text] [Related]
30. [Virus inactivation in the preparation of plasma proteins].
Benedikter H; Mohr H
Beitr Infusionther Klin Ernahr; 1987; 18():25-9. PubMed ID: 3125829
[No Abstract] [Full Text] [Related]
31. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
32. The development of plasma derivatives for clinical use. A symposium summary.
Deutsch HF
Vox Sang; 1972; 23(1):147-50. PubMed ID: 5081010
[No Abstract] [Full Text] [Related]
33. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
34. Current strategies to prevent transmission of prions by human plasma derivatives.
Burnouf T; Padilla A
Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
[TBL] [Abstract][Full Text] [Related]
35. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
36. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
37. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
[TBL] [Abstract][Full Text] [Related]
38. Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry.
Bruce SJ; Tavazzi I; Parisod V; Rezzi S; Kochhar S; Guy PA
Anal Chem; 2009 May; 81(9):3285-96. PubMed ID: 19323527
[TBL] [Abstract][Full Text] [Related]
39. Safety of human blood products: inactivation of retroviruses by heat treatment at 60 degrees C.
Hilfenhaus J; Mauler R; Friis R; Bauer H
Proc Soc Exp Biol Med; 1985 Apr; 178(4):580-4. PubMed ID: 2984690
[TBL] [Abstract][Full Text] [Related]
40. [Properties and virus safety of a pasteurized antithrombin III concentrate].
Karges HE; Fuhge P; Heimburger N
Arzneimittelforschung; 1987 Jul; 37(7):756-8. PubMed ID: 2823838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
